StemCell Institute Inc. Stock

Equities

7096

JP3399640006

Healthcare Facilities & Services

Market Closed - Japan Exchange 02:00:00 2024-05-13 am EDT 5-day change 1st Jan Change
1,928 JPY +0.94% Intraday chart for StemCell Institute Inc. +3.99% -10.07%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 2.57B 16.49M Sales 2025 * 3.1B 19.89M Capitalization 19.57B 126M
Net income 2024 * 380M 2.44M Net income 2025 * 480M 3.08M EV / Sales 2024 * 7.62 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 6.31 x
P/E ratio 2024 *
51.5 x
P/E ratio 2025 *
40.8 x
Employees 92
Yield 2024 *
-
Yield 2025 *
0.79%
Free-Float 22.33%
More Fundamentals * Assessed data
Dynamic Chart
Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023. CI
Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 24-SEP-2023. CI
Cuorips Inc. has completed an IPO in the amount of ¥3.432 billion. CI
Cuorips Inc. has filed an IPO. CI
Certain Common Stock of StemCell Institute Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2021. CI
Certain Common Stock of StemCell Institute Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2021. CI
StemCell Institute Inc. has completed an IPO in the amount of ¥2.32624 billion. CI
StemCell Institute Inc. has filed an IPO. CI
CUORiPS Inc. announced that it expects to receive ¥2 billion in funding from Asahi Intecc Co., Ltd., StemCell Institute Inc., Dai-Dan Co., Ltd., Taiko Pharmaceutical Co.,Ltd., Kyoto University Innovation Capital Co., Ltd., Terumo Corporation and other investors CI
StemCell Institute Inc. has withdrawn its IPO. CI
StemCell Institute Inc. has filed an IPO. CI
TrimGen Holdings Co., Ltd completed the acquisition of 56.57% stake in StemCell Institute Inc. from Nihon Trim Co., Ltd.. CI
TrimGen Holdings Co., Ltd agreed to acquire 56.57% stake in StemCell Institute Inc. from for Nihon Trim Co., Ltd. approximately ¥940 million. CI
Nihon Trim Co., Ltd. completed the acquisition of 50.1% stake in Stemcell Institute from Kunimatsu Yamamoto and funds sponsored by Japan Asia Investment Co. Ltd., JAFCO Co., Ltd. and Ant Capital Partners Co., Ltd. CI
Nihon Trim Co., Ltd. agreed to acquire a 50.1% stake in Stemcell Institute from Kunimatsu Yamamoto and funds sponsored by Japan Asia Investment Co. Ltd., JAFCO Co., Ltd. and Ant Capital Partners Co., Ltd. for approximately ¥790 million. CI
More news
1 day+0.94%
1 week+3.99%
Current month+2.88%
1 month+7.11%
3 months-4.79%
6 months-12.00%
Current year-10.07%
More quotes
1 week
1 820.00
Extreme 1820
1 930.00
1 month
1 732.00
Extreme 1732
1 959.00
Current year
1 728.00
Extreme 1728
2 358.00
1 year
1 728.00
Extreme 1728
3 285.00
3 years
1 165.00
Extreme 1165
3 610.00
5 years
1 165.00
Extreme 1165
3 610.00
10 years
1 165.00
Extreme 1165
3 610.00
More quotes
Managers TitleAgeSince
President 51 13-08-31
Chief Administrative Officer 53 16-05-31
Sales & Marketing - -
Members of the board TitleAgeSince
President 51 13-08-31
Chief Administrative Officer 53 16-05-31
Director/Board Member 79 15-05-31
More insiders
Date Price Change Volume
24-05-13 1,928 +0.94% 17 100
24-05-10 1,910 +1.92% 13,700
24-05-09 1,874 +1.30% 6,000
24-05-08 1,850 -0.22% 2,100

Delayed Quote Japan Exchange, May 13, 2024 at 02:00 am EDT

More quotes
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW